Recent News

• 06.10.2025 - Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
• 06.10.2025 - Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
• 06.04.2025 - Jefferies Global Healthcare Conference
• 06.04.2025 - Jefferies Global Healthcare Conference
• 05.28.2025 - Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
• 05.28.2025 - Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
• 05.09.2025 - Oliver McCammon
• 05.09.2025 - Oliver McCammon
• 05.08.2025 - Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
• 05.08.2025 - Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Recent Filings

• 06.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - 8-K Current report
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material